MUNICH, February 24, 2017 – Roche is regarded as a leading company in lung cancer as well as in the areas of breast/ovarian cancer, according to the results of two new studies conducted among oncologists at the end of 2016 by Kantar Health, a leading global healthcare consulting and market research firm.
The company ratings are based on 20 criteria, leading to an overall image score, including:
- Aspects of the products (e.g., product quality, innovative products)
- Economy (e.g., cost/performance ratio)
- Service (e.g., services for healthcare professionals, useful information/services for patients)
- Care (e.g., continuity of care, competence of the sales representative, sensitivity to physicians’ problems)
- Society/politics (e.g., socially responsible role, competence in health policy issues)
The criteria that have the highest impact on the valuation of pharmaceutical companies are product quality, providing good scientific information, innovative products and competence of the sales representative.
Lung Cancer: Roche leads in spontaneous preference, image and Net Promoter Score
In addition to the image review, oncologists answered an open-ended question on which companies they particularly appreciate in the field of lung cancer. In this discipline Roche dominates among the 61 hospital-based physicians as well as among the 29 office-based physicians surveyed.
Roche also assumes a clear leading role among the nine evaluated companies and has the best overall image value for most of the image criteria. From the office-based physicians' point of view, the advantage is clear. The field is somewhat closer together from the hospital-based physicians' point of view. Here, the distances to the second-placed company Boehringer Ingelheim and Novartis as a third-placed company are somewhat shorter.
The Net Promoter Score, on the other hand, is clearly the best for Roche, followed once again by Boehringer Ingelheim and Novartis.
Breast/ovarian cancer: Roche ahead of Novartis and AstraZeneca in spontaneous preference, image and Net Promoter Score
When physicians evaluated seven companies in the area of breast/ovarian cancer, Roche is clearly ranked first in all dimensions: spontaneous appreciation, image criteria and Net Promoter Score.
Roche scores the best value in the image survey for each criterion with a clear distance to the second-placed company. Novartis and AstraZeneca are ranked 2 and 3, respectively, in terms of overall score but are clearly behind Roche.
In the Net Promoter Score Roche also achieves very high scores, again followed by Novartis and AstraZeneca.
The full reports "Corporate Image 2016" will be partly individualized for your company and are available for purchase. Contact Dr. Katja Zacharias, Senior Consultant, Marketing Insights, at +49 89 56001929 or email@example.com.
These results may only be published under the byline “Kantar Health.”
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit www.kantarhealth.com